Clinical Pathologic Alterations Associated with Subcutaneous Administration of Recombinant Human Interleukin-4 to Cynomolgus Monkeys

Recombinant human interleukin 4 (rhuIL-4) is a candidate for the treatment of refractory cancer based on its potential to enhance immune function. Recombinant human IL-4 was administered subcutaneously at 0, 1, 5, or 25 μg/kg/day for 28 days with a 14-day recovery to male and female cynomolgus monke...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Toxicologic pathology 1993-01, Vol.21 (1), p.46-53
Hauptverfasser:	Gossett, Kent A., Barbolt, Thomas A., Cornacoff, Joel B., Zelinger, David J., Dean, Jack H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Atrophy - chemically induced Biological and medical sciences Blood Coagulation - drug effects Blood Proteins - metabolism Drug toxicity and drugs side effects treatment Erythrocyte Count - drug effects Female Granulocytes - drug effects Granulocytes - pathology Hematocrit Hemoglobins - drug effects Humans Hyperplasia - chemically induced Injections, Subcutaneous Interleukin-4 - toxicity Leukocyte Count - drug effects Macaca fascicularis Male Medical sciences Neoplasms, Experimental - drug therapy Neoplasms, Experimental - pathology Pharmacology. Drug treatments Prothrombin Time Recombinant Proteins - toxicity Seminiferous Tubules - drug effects Seminiferous Tubules - pathology Toxicity: blood Vasculitis - chemically induced Vasculitis - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!